Medisi America
  • Home
  • We Are
  • Services
  • News
  • Contact Us
  • en EN
    • en EN
    • fr FR
    • de DE
    • it IT
    • pt PT
    • ru RU
    • es ES

COFEPRIS Challenges 2020

By Medisi America on 21 febrero, 2020

Since December 1st, 2018 a historical change in administration that consisted of a new president who is committed to Public Office cleansing of corrupt and unequal practices had a strong impact on the whole country course of operation. Many institutions were eliminated or were audited and restructured. 

Cofepris was audited and analyzed for permanence or removal but was decided to stay active. This, however, caused a complete pause in real operation for almost a whole Quarter of the year; therefore in between 2019-2020, we observed a complete change in staff and certain evaluation criteria.

The main changes to this day include grouping criteria, better answering time for traditional track processes versus previous years and a tendency to avoid any preferential treatment tracks (like Third Authorized Party processes).

Despite initial setbacks, right now answering times are becoming much better than in any previous years which becomes a strong solution given by this administration.

-Copyright 2020 Medisi America. Replication and quote of this content are subject to International Author Law.

Posted in News.
Share
←  NewerCOFEPRIS Evolves
Older  →ResMed ventilators recall is Class I

Entradas recientes

  • COFEPRIS Evolves
  • COFEPRIS Challenges 2020
  • ResMed ventilators recall is Class I
  • Finding a non-invasive way to predict effectiveness of cancer therapy.

NEWS

  • Conferences
  • News
  • Science
  • Technology

Deja una respuesta Cancelar la respuesta

Tu dirección de correo electrónico no será publicada. Los campos obligatorios están marcados con *

Related Posts

  • 10 octubre, 2019

    Study: Abbott, Edwards may have mislabeled hundreds of patient deaths

    Abbott (NYSE:ABT) and Edwards Lifesciences (NYSE:EW) may have mislabeled patient deaths as injuries or device malfunctions in hundreds of FDA adverse event reports involving their transcatheter aortic or mitral valve replacement devices, according to a new study. The study by JAMA Internal Medicine editor Dr. Rita Redberg, former FDA unique device identification (UDI) external program manager Madris Tomes and others examined a total …

  • 10 octubre, 2019

    ‘Electronic tongues’ may help diagnose early stage bladder cancer

    New research presents a complex electronic device as a possible new, efficient, simple, and cost-effective way of detecting bladder cancer in its early stages and monitoring people living with bladder cancer. In a quest to find a better way of diagnosing bladder cancer, Spain-based researchers from the Polytechnic University of Valencia (UPV), the La Fe …

  • 10 octubre, 2019

    AI-enhanced ECGs may soon assess overall health

    Scientists have trained an artificial intelligence tool to predict sex and estimate age from electrocardiogram readouts. They suggest that, with further development, the tool could soon be helping doctors to assess the overall health of their patients. An electrocardiogram, also known as an ECG or EKG, is a painless, simple test that records the electrical …

  • 18 junio, 2019

    Artificial intelligence better than humans at spotting lung cáncer

    Researchers have used a deep-learning algorithm to detect lung cancer accurately from computed tomography scans. The results of the study indicate that artificial intelligence can outperform human evaluation of these scans. If you want to read more about this news click here.

  • © 2025 MEDISI America - All rights reserved
  • Home
  • We Are
  • Services
  • News
  • Contact Us
  • en EN
    • en EN
    • fr FR
    • de DE
    • it IT
    • pt PT
    • ru RU
    • es ES